Commitments and Contingencies (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 17, 2022	Sep. 30, 2022	Sep. 12, 2022	Dec. 31, 2021
Commitments and Contingencies (Details) [Line Items]
Underwriting agreement, description		The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.
Preferred stock shares authorized		1,000,000		1,000,000
Merger consideration description		The total consideration to be paid to the holders of Scilex common stock at Closing (the “Merger Consideration”) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the “Closing Date”); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (“VCKA Common Stock”).
Common stock aggregate value (in Dollars)		$ 1,500,000,000
Net tangible assets (in Dollars)		$ 5,000,001
Aggregate percentage	75.00%
Warrants percentage	40.00%
Balance in the trust account (in Dollars)	$ 25,000,000
Deferred underwriting commission percentage	50.00%
Underwriting commission payable percentage	50.00%
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Preferred stock shares authorized		20,000,000
Stock authority to issue		750,000,000
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Preferred stock shares authorized		45,000,000
Stock authority to issue		785,000,000
Series A Preferred Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Preferred Stock shares		1
Series A preferred stock, par value (in Dollars per share)			$ 0.0001
Series of Individually Immaterial Business Acquisitions [Member]
Commitments and Contingencies (Details) [Line Items]
Business combination, description		The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the “Preferred Consideration”. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA’s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.
Scilex Common Stock [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Preferred Stock, par value (in Dollars per share)		$ 0.0001